Cagrilintide

Cagrilintide · 10mg

Weekly amylin analog · satiety by another route · the other half of CagriSema, under FDA review

  • Metabolic
Phase 3 complete · under review in United States since Dec 2025
🇺🇸 United States · Under review

The approval application has been filed and is under review in United States (CagriSema (con semaglutida)). Novo Nordisk developed cagrilintide to be used with semaglutide (CagriSema). In REDEFINE 1 (3,417 adults, 68 weeks) the combination reached 22.7% weight loss and cagrilintide alone 11.8%, versus 2.3% on placebo (all participants: 20.4%, 11.5% and 3.0%). In type 2 diabetes (REDEFINE 2) the combination lost 13.7%. Against tirzepatide (REDEFINE 4, February 2026) it lost 20.2% vs 23.6% and did not reach non-inferiority; the application remains under review and Novo Nordisk guides to a decision in late 2026. Cagrilintide alone entered its own phase 3 programme (RENEW) in late 2025, with no results yet. The FDA application was filed on December 18, 2025. Next step: the FDA's decision.

FDA · solicitud de CagriSema, 18-dic-2025 · Novo Nordisk · REDEFINE 1 (NEJM 2025), REDEFINE 2 (NEJM 2025), REDEFINE 4 (23-feb-2026)

Main pick for Lose weightClinical backing
OverviewProtocolsPreparationCombinationsEvidenceQuestions

Overview

What has it been researched for?

  • Controls appetite and satietyMain focus
  • Lowers body weightWell studied
  • Improves glucose controlUnder study

It makes sense if you want

  • Lose weight & curb appetite
  • Lose weight — most potent

When you notice it

  1. First signs · week 4
  2. Full effect · week 20

Tools

Reconstitution calculatorConverts mg to units (U-100), volume and concentration.Open calculator →Preparation (step by step)How to reconstitute, store and handle, with good practice.See the guide →My trackingLog doses, results and notes per goal, in the app.Go to my tracking →

Evidence and studies

See studies →
Clinical backing(3)
Before you start(22)

Before you start, check first if

  • Personal or family history of medullary thyroid cancer or MEN2
  • Active cancer or oncology treatment in the last 5 years
  • Pregnancy or breastfeeding
  • Gastroparesis or slow gastric emptying
  • Active eating disorder
  • Oral contraceptive (the pill)
  • Severe heart disease or recent cardiac event
  • Major surgery in the last 3 months
  • Type 1 diabetes
  • Type 2 diabetes / prediabetes
  • Gallbladder disease or gallstones
  • GLP-1 (Ozempic, Wegovy, Mounjaro, Saxenda)
  • Severe liver impairment
  • Severe kidney impairment
  • Insulin
  • Blood pressure meds
  • Thyroid meds
  • History of pancreatitis
  • Planning a pregnancy in the next 3 months
  • Diabetic retinopathy
  • Sulfonylureas / metformin
  • Thyroid disorder

Protocols

Protocols

SBL protocol · based on published studies

One reference protocol: why, when and how.

Official SBL

Official SBL
148121620
  • Weeks 1–4 · 0.25 mg
  • Weeks 5–8 · 0.5 mg
  • Weeks 9–12 · 1 mg
  • Weeks 13–16 · 1.7 mg
  • Weeks 17–20 · 2.4 mg

20 applications in the cycle

Why

SuperBio's reference protocol: the balance between effect and tolerance.

When

Timing
Any time of day
Frequency
1 times a week
Duration
20 weeks
Break
No break

How

Route
Subcutaneous
Weeks 1–4
0.25 mg · 5 u
Weeks 5–8
0.5 mg · 10 u
Weeks 9–12
1 mg · 20 u
Weeks 13–16
1.7 mg · 34 u
Weeks 17–20
2.4 mg · 48 u
0501005
5 u= 0.25 mg

Preparation

Quick reference

Vial10 mg
Diluent2 ml
Concentration5 mg/ml
1 unit =0.05 mg

How to prepare it, step by step

  1. Wipe the vial stopper and the diluent stopper with alcohol.
  2. With the 3 ml syringe, draw 2 ml of bacteriostatic water.
  3. Add it slowly down the side of the vial, not onto the powder.
  4. Swirl the vial gently until it dissolves. Do not shake it.
Diluent
Bacteriostatic water

Example dose

0501005
5 u= 0.25 mg

100-unit U-100 insulin syringe · Starting dose of its protocol, with 2 ml of water in the 10 mg vial.

Open calculator →See the guide →

Combinations

What it pairs with

From here you can go to

Evidence

Each effect with its evidence level and, where available, its source.

Clinical backing(3)
  • Controls appetite and satietyPhase 3Source under review
  • Lowers body weightPhase 3Source under review
  • Improves glucose controlHuman studySource under review

Every batch comes with its certificate of analysis: identity and purity verified with its QR code.

Verify your batch →
The scienceMechanisms, studies and references

Amylin analog

Questions

Frequently asked questions

What is it reconstituted with, and how much?

With bacteriostatic water: 2 ml into the 10 mg vial, giving 5 mg/ml.

What dose does it start with?

0.25 → 2.4 mg, 1×/semana, following the Official SBL protocol.

How long is the cycle, and how long does a vial last?

20 weeks. At the starting dose, the 10 mg vial lasts ~5 sem.

How is it applied?

Subcutaneous.

When should I check with my doctor first?

Check with your doctor first if: Personal or family history of medullary thyroid cancer or MEN2, Active cancer or oncology treatment in the last 5 years, Pregnancy or breastfeeding, Gastroparesis or slow gastric emptying, Active eating disorder.

What is it combined with?

Goes well with Tirzepatide. The why, in the Combinations tab.

How do I check my batch?

With the vial code in the verifier: you see the identity and purity certificate of your batch.

Verify your batch →